(Attachment) Designation of “Shitei Yakubutsu” (Designated Substances

Total Page：16

File Type：pdf, Size：1020Kb

(Attachment) Designation of “Shitei Yakubutsu” (designated substances) based on the provision of the Act on Securing Quality, Efficacy and Safety of Pharmaceuticals, Medical Devices, Regenerative and Cellular Therapy Products, Gene Therapy Products, and Cosmetics (1960, Law No.145) In order to clarify the regulation under the Act on Securing Quality, Efficacy and Safety of Pharmaceuticals, Medical Devices, Regenerative and Cellular Therapy Products, Gene Therapy Products, and Cosmetics (hereinafter referred to as the “Act”), the Minister of Health, Labour and Welfare of Japan proposes to designate the following substances as “Shitei Yakubutsu” (designated substances). Manufacture, import, sale, simple ownership and the use of “designated substances” are banned except for the “proper uses” (see below). ● The proposed substances as “Shitei Yakubutsu” ※Abbreviation is put in parentheses. 1. 4-Acetoxy-N-isopropyl-N-metyltryptamine（4AcO-MIPT） 2. 2-Amino-1-(4-bromo-2,5-dimethoxyphenyl)ethanone（bk-2C-B） 3. 2-(4-Allyloxy-3,5-dimethoxyphenyl)ethanamine（Allylescaline） 4. 2-Ethylamino-1-(4-methylphenyl)hexan-1-one 5. N-Ethyl-4-hydroxy-N-methyltryptamine（4-OH-MET） 6. 1-(4-Ethoxy-3,5-dimethoxyphenyl)propan-2-amine（3C-E） 7. 5-Chloro-3-ethyl-N-[4-(piperidin-1-yl)phenethyl]-1H-indole-2-carboxamide（Org27569） 8. 1-(3,4-Dimethylphenyl)-2-(pyrrolidin-1-yl)pentan-1-one（3,4-Dimethyl-α-PVP） 9. 2-(2,5-Dimethoxy-4-propylphenyl)ethanamine（2C-P） 10. Naphthalen-1-yl(1-pentyl-5-phenyl-1H-pyrrol-3-yl)methanone（JWH-145） 11. 4-Hydroxy-N-isopropyl-N-metyltryptamine（4OH-MIPT） 12. [5-(3-Fluorophenyl)-1-pentyl-1H-pyrrol-3-yl](naphthalen-1-yl)methanone（JWH-368） 13. 1-(4-Fluorophenyl)-2-(methylamino)hexan-1-one 14. N-Benzyl-1-(5-fluoropentyl)-1H-indole-3-carboxamide（5F-SDB-006） 15. N-(2-Methoxybenzyl)-2-(2,5-dimethoxy-4-metylphenyl)ethanamine（25D-NBOMe） 16. 1-(2-Methoxy-4,5-methylenedioxyphenyl)-2-(methylamino)propan-1-one （2-Methoxy-4,5-methylenedioxy methcathinone） ● The “proper uses” for all “Shitei Yakubutsu”, designated based on the Act 1. To be used for researches or tests at the government, the local governments, agencies thereof, technical colleges, inter-university research institutes, the independent administrative agencies and the local independent administrative agencies 2. To be used for tests under the Act, and 3. To be used for forensic use .

Copy Link

Recommended publications

Peakal: Protons I Have Known and Loved — Fifty Shades of Grey-Market Spectra
PeakAL: Protons I Have Known and Loved — Fifty shades of grey-market spectra Stephen J. Chapman* and Arabo A. Avanes * Correspondence to: Isomer Design, 4103-210 Victoria St, Toronto, ON, M5B 2R3, Canada. E-mail: [email protected] 1H NMR spectra of 28 alleged psychedelic phenylethanamines from 15 grey-market internet vendors across North America and Europe were acquired and compared. Members from each of the principal phenylethanamine families were analyzed: eleven para- substituted 2,5-dimethoxyphenylethanamines (the 2C and 2C-T series); four para-substituted 3,5-dimethoxyphenylethanamines (mescaline analogues); two β-substituted phenylethanamines; and ten N-substituted phenylethanamines with a 2-methoxybenzyl (NBOMe), 2-hydroxybenzyl (NBOH), or 2,3-methylenedioxybenzyl (NBMD) amine moiety. 1H NMR spectra for some of these compounds have not been previously reported to our knowledge. Others have reported on the composition of “mystery pills,” single-dose formulations obtained from retail shops and websites. We believe this is the first published survey of bulk “research chemicals” marketed and sold as such. Only one analyte was unequivocally misrepresented. This collection of experimentally uniform spectra may help forensic and harm-reduction organizations identify these compounds, some of which appear only sporadically. The complete spectra are provided as supplementary data.[1] Keywords: 1H NMR, drug checking, grey markets, research chemicals, phenylethanamines, N-benzyl phenylethanamines, PiHKAL DOI: http://dx.doi.org/10.16889/isomerdesign-1 Published: 1 August 2015 Version: 1.03 “Once you get a serious spectrum collection, Nevertheless, an inherent weakness of grey markets is the the tendency is to push it as far as you can.”1 absence of regulatory oversight.
[Show full text]
Colorimetric Approaches to Drug Analysis and Applications – a Review
REVIEW ARTICLE Am. J. PharmTech Res. 2019; 9(01) ISSN: 2249-3387 Journal home page: http://www.ajptr.com/ Colorimetric Approaches To Drug Analysis And Applications – A Review Sowjanya Gummadi*, Mohana Kommoju Department of Pharmaceutical Analysis, Institute of Pharmacy, GITAM (Deemed to be University), Visakhapatnam-530045, Andhra Pradesh, India ABSTRACT The main purpose of this review is to highlight the importance of colorimetric approaches to drug analysis both in dosage forms as well as biological samples. Colorimetric methods using colorimetric reagents are highly sensitive, specific and an easy way of determining various analytes in a variety of matrices within a short time. The colorimetric procedures discussed are statistically validated and reported in various quality control laboratories. Hence in the present review significance of colorimetric procedures, various reagents used along with principles and applications are mentioned. Key words: Colorimetric approaches, sensitive, matrices, quality control, applications. *Corresponding Author Email: [email protected] Received 01 November 2018, Accepted 23 December 2018 Please cite this article as: Gummadi S et al., Colorimetric Approaches To Drug Analysis And Applications – A Review. American Journal of PharmTech Research 2019. Gummadi et. al., Am. J. PharmTech Res. 2019; 9(01) ISSN: 2249-3387 INTRODUCTION Colorimetry is a technique which involves the quantitative estimation of colors frequently used in biochemical investigation. Color can be produced by any substance when it binds with color forming chromogens. The difference in color intensity results in difference in the absorption of light. The intensity of color is directly proportional to the concentration of the compound being measured.1 Wavelength between 380 nm to 780 nm forms the visible band of light in electromagnetic spectrum.
[Show full text]
Virginia Acts of Assembly -- 2021 Special Session I
VIRGINIA ACTS OF ASSEMBLY -- 2021 SPECIAL SESSION I CHAPTER 110 An Act to amend and reenact §§ 3.2-4112, 3.2-4113, 3.2-4114.2, 3.2-4115, 3.2-4116, 3.2-4118, 3.2-4119, 18.2-247, 18.2-251.1:3, 54.1-3401, and 54.1-3446 of the Code of Virginia, relating to industrial hemp; emergency. [H 2078] Approved March 12, 2021 Be it enacted by the General Assembly of Virginia: 1. That §§ 3.2-4112, 3.2-4113, 3.2-4114.2, 3.2-4115, 3.2-4116, 3.2-4118, 3.2-4119, 18.2-247, 18.2-251.1:3, 54.1-3401, and 54.1-3446 of the Code of Virginia are amended and reenacted as follows: § 3.2-4112. Definitions. As used in this chapter, unless the context requires a different meaning: "Cannabis sativa product" means a product made from any part of the plant Cannabis sativa, including seeds thereof and any derivative, extract, cannabinoid, isomer, acid, salt, or salt of an isomer, whether growing or not, with a concentration of tetrahydrocannabinol that is greater than that allowed by federal law. "Deal" means to buy temporarily possess industrial hemp grown in compliance with state or federal law and to sell such industrial hemp to a person who that (i) processes industrial hemp in compliance with state or federal law or has not been processed and (ii) sells industrial hemp to a person who processes industrial hemp in compliance with state or federal law was not grown and will not be processed by the person temporarily possessing it.
[Show full text]
Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances Joshua Zolton Seither [email protected]
Florida International University FIU Digital Commons FIU Electronic Theses and Dissertations University Graduate School 4-25-2018 Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances Joshua Zolton Seither [email protected] DOI: 10.25148/etd.FIDC006565 Follow this and additional works at: https://digitalcommons.fiu.edu/etd Part of the Chemistry Commons Recommended Citation Seither, Joshua Zolton, "Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances" (2018). FIU Electronic Theses and Dissertations. 3823. https://digitalcommons.fiu.edu/etd/3823 This work is brought to you for free and open access by the University Graduate School at FIU Digital Commons. It has been accepted for inclusion in FIU Electronic Theses and Dissertations by an authorized administrator of FIU Digital Commons. For more information, please contact [email protected]. FLORIDA INTERNATIONAL UNIVERSITY Miami, Florida APPLICATION OF HIGH RESOLUTION MASS SPECTROMETRY FOR THE SCREENING AND CONFIRMATION OF NOVEL PSYCHOACTIVE SUBSTANCES A dissertation submitted in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY in CHEMISTRY by Joshua Zolton Seither 2018 To: Dean Michael R. Heithaus College of Arts, Sciences and Education This dissertation, written by Joshua Zolton Seither, and entitled Application of High- Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances, having been approved in respect to style and intellectual content, is referred to you for judgment. We have read this dissertation and recommend that it be approved. _______________________________________ Piero Gardinali _______________________________________ Bruce McCord _______________________________________ DeEtta Mills _______________________________________ Stanislaw Wnuk _______________________________________ Anthony DeCaprio, Major Professor Date of Defense: April 25, 2018 The dissertation of Joshua Zolton Seither is approved.
[Show full text]
Model Scheduling New/Novel Psychoactive Substances Act (Third Edition)
Model Scheduling New/Novel Psychoactive Substances Act (Third Edition) July 1, 2019. This project was supported by Grant No. G1799ONDCP03A, awarded by the Office of National Drug Control Policy. Points of view or opinions in this document are those of the author and do not necessarily represent the official position or policies of the Office of National Drug Control Policy or the United States Government. © 2019 NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. This document may be reproduced for non-commercial purposes with full attribution to the National Alliance for Model State Drug Laws. Please contact NAMSDL at [email protected] or (703) 229-4954 with any questions about the Model Language. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: NATIONAL ALLIANCE FOR MODEL STATE DRUG 1 LAWS, 1335 North Front Street, First Floor, Harrisburg, PA, 17102-2629. Model Scheduling New/Novel Psychoactive Substances Act (Third Edition)1 Table of Contents 3 Policy Statement and Background 5 Highlights 6 Section I – Short Title 6 Section II – Purpose 6 Section III – Synthetic Cannabinoids 13 Section IV – Substituted Cathinones 19 Section V – Substituted Phenethylamines 23 Section VI – N-benzyl Phenethylamine Compounds 25 Section VII – Substituted Tryptamines 28 Section VIII – Substituted Phenylcyclohexylamines 30 Section IX – Fentanyl Derivatives 39 Section X – Unclassified NPS 43 Appendix 1 Second edition published in September 2018; first edition published in 2014. Content in red bold first added in third edition. © 2019 NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. This document may be reproduced for non-commercial purposes with full attribution to the National Alliance for Model State Drug Laws.
[Show full text]
Volume 33, Issue 11 Virginia Register of Regulations January 23, 2017 1181 PUBLICATION SCHEDULE and DEADLINES
VOL. 33 ISS. 11 PUBLISHED EVERY OTHER WEEK BY THE VIRGINIA CODE COMMISSION JANUARY 23, 2017 VOL TABLE OF CONTENTS Register Information Page ......................................................................................................................................... 1181 Publication Schedule and Deadlines ....................................................................................................................... 1182 Petitions for Rulemaking ............................................................................................................................................ 1183 Notices of Intended Regulatory Action ................................................................................................................. 1184 Regulations ....................................................................................................................................................................... 1186 8VAC20-22. Licensure Regulations for School Personnel (Final) ........................................................................................ 1186 9VAC25-720. Water Quality Management Planning Regulation (Final) .............................................................................. 1190 12VAC5-481. Virginia Radiation Protection Regulations (Final) ......................................................................................... 1199 12VAC30-30. Groups Covered and Agencies Responsible for Eligibility Determination (Final) ........................................ 1217 12VAC30-50.
[Show full text]
Förordning Om Ändring I Förordningen (1992:1554) Om Kontroll Av Narkotika;
Príloha 11 k rozhodnutiu švédskych úradov vlády 22. februára 2018 § 79 1. ------IND- 2018 0079 S-- SK- ------ 20180302 --- --- PROJET Zbierka zákonov Švédska SFS Published on issued on 1 March 2018. The government hereby lays down1 that Annex 1 to the Ordinance (1992:1554) on the control of narcotic drugs2 shall read as set out below. This ordinance shall enter into force on 10 April 2018. On behalf of the Government ANNIKA STRANDHÄLL Lars Hedengran (Ministry of Health and Social Affairs) 1 See Directive (EU) 2015/1535 of the European Parliament and of the Council of 9 September 2015 laying down a procedure for the provision of information in the field of technical regulations and of rules on Information Society services. 2 Ordinance reprinted as 1993:784. 1 SFS Annex 13 List of substances to be considered narcotic drugs according to the Narcotic Drugs Punishments Act Stimulants of the central nervous system ethylamphetamine (2-ethylamino-1-phenylpropane) fenethylline [1-phenyl-1-piperidyl-(2)-methyl]acetate 1-phenyl-2-butylamine N-hydroxyamphetamine propylhexedrine 4-methylthioamphetamine (4-MTA) modafinil 4-methoxy-N-methylamphetamine (PMMA, 4-MMA) 2,5-dimethoxy-4-ethylthiophenethylamine (2C-T-2) 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7) 4-iodo-2,5-dimethoxyphenethylamine (2C-I) 2,4,5-trimethoxyamphetamine (TMA-2) 4-methylmethcathinone (mephedrone) 4-fluoramphetamine 1-(4-methoxyphenyl)-2-(methylamino)propan-1-one (methedrone) 1-(1,3-benzodioxol-5-yl)-2-pyrrolidin-1-yl-pentan-1-one (MDPV) 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butan-1-one
[Show full text]
Appendix-2Final.Pdf 663.7 KB
North West ‘Through the Gate Substance Misuse Services’ Drug Testing Project Appendix 2 – Analytical methodologies Overview Urine samples were analysed using three methodologies. The first methodology (General Screen) was designed to cover a wide range of analytes (drugs) and was used for all analytes other than the synthetic cannabinoid receptor agonists (SCRAs). The analyte coverage included a broad range of commonly prescribed drugs including over the counter medications, commonly misused drugs and metabolites of many of the compounds too. This approach provided a very powerful drug screening tool to investigate drug use/misuse before and whilst in prison. The second methodology (SCRA Screen) was specifically designed for SCRAs and targets only those compounds. This was a very sensitive methodology with a method capability of sub 100pg/ml for over 600 SCRAs and their metabolites. Both methodologies utilised full scan high resolution accurate mass LCMS technologies that allowed a non-targeted approach to data acquisition and the ability to retrospectively review data. The non-targeted approach to data acquisition effectively means that the analyte coverage of the data acquisition was unlimited. The only limiting factors were related to the chemical nature of the analyte being looked for. The analyte must extract in the sample preparation process; it must chromatograph and it must ionise under the conditions used by the mass spectrometer interface. The final limiting factor was presence in the data processing database. The subsequent study of negative MDT samples across the North West and London and the South East used a GCMS methodology for anabolic steroids in addition to the General and SCRA screens.
[Show full text]
La Mescaline
Université de Lille Faculté de Pharmacie de Lille Année Universitaire 2017/2018 THESE POUR LE DIPLOME D'ETAT DE DOCTEUR EN PHARMACIE Soutenue publiquement le 31 octobre 2018 Par M. RIDOUX Florent _____________________________ Description d’une famille d’hallucinogènes : les phényléthylamines psychédéliques, du peyotl aux nouvelles drogues de synthèse _____________________________ Membres du jury : Président : ALLORGE Delphine, Professeur des Universités-Praticien Hospitalier, Faculté de Pharmacie, Université de Lille Assesseur : BORDAGE Simon, Maître de Conférences des Universités, Faculté de Pharmacie, Université de Lille Membre(s) extérieur : DEHEUL Sylvie, Praticien Hospitalier, CEIP-A, CHU de Lille Faculté de Pharmacie de Lille 3, rue du Professeur Laguesse - B.P. 83 - 59006 LILLE CEDEX 03.20.96.40.40 - : 03.20.96.43.64 http://pharmacie.univ-lille2.fr Université de Lille Président : Jean-Christophe CAMART Premier Vice-président : Damien CUNY Vice-présidente Formation : Lynne FRANJIÉ Vice-président Recherche : Lionel MONTAGNE Vice-président Relations Internationales : François-Olivier SEYS Directeur Général des Services : Pierre-Marie ROBERT Directrice Générale des Services Adjointe : Marie-Dominique SAVINA Faculté de Pharmacie Doyen : Bertrand DÉCAUDIN Vice-Doyen et Assesseur à la Recherche : Patricia MELNYK Assesseur aux Relations Internationales : : Philippe CHAVATTE Assesseur à la Vie de la Faculté et aux Relations avec le Monde Professionnel : Thomas MORGENROTH Assesseur à la Pédagogie : Benjamin BERTIN Assesseur à la Scolarité : Christophe BOCHU Responsable des Services : Cyrille PORTA Liste des Professeurs des Universités - Praticiens Hospitaliers Civ. NOM Prénom Laboratoire Mme ALLORGE Delphine Toxicologie M. BROUSSEAU Thierry Biochimie M. DÉCAUDIN Bertrand Pharmacie Galénique M. DEPREUX Patrick ICPAL M. DINE Thierry Pharmacie clinique Mme DUPONT-PRADO Annabelle Hématologie M.
[Show full text]
Identifying the Experiences of Young Sexual Minority
Goodyear et al. Harm Reduction Journal (2020) 17:23 https://doi.org/10.1186/s12954-020-00365-4 RESEARCH Open Access “Am I gonna get in trouble for acknowledging my will to be safe?”: Identifying the experiences of young sexual minority men and substance use in the context of an opioid overdose crisis Trevor Goodyear1,2,3, Caroline Mniszak1,4, Emily Jenkins2, Danya Fast1,4 and Rod Knight1,4* Abstract Background: North America and other parts of the globe are in the midst of a public health emergency related to opioid overdoses and a highly contaminated illicit drug supply. Unfortunately, there is a substantial gap in our understandings about how this crisis affects key populations not conventionally identified within overdose-related surveillance data. This gap is particularly pronounced for gay, bisexual, and other men who have sex with men (sexual minority men)—a population that experiences substance use-related inequities across adolescence and young adulthood. Methods: We draw on in-depth semi-structured interviews conducted in 2018 with a diverse sample (N = 50) of sexual minority men ages 15–30 who use substances and live in Vancouver, Canada, to identify how patterns and contexts of substance use are occurring in the context of the opioid overdose crisis. Results: Our analysis revealed three themes: awareness, perceptions, and experiences of risk; strategies to mitigate risk; and barriers to safer substance use. First, participants described how they are deeply impacted by the contaminated illicit drug supply, and how there is growing apprehension that fatal and non-fatal overdose risk is high and rising.
[Show full text]
25X-Nbome” Type Molecules Available Information on the Diffusion of a Class of NPS in France
“25x-NBOMe” type molecules Available information on the diffusion of a class of NPS in France Magali Martinez, Agnès Cadet-Taïrou, Thomas Néfau with the TREND network coordinators June 2017 1 Contributors Aurélie Lazès-Charmetant (Bordeaux), Sébastien Lose (Lille), Nina Tissot (Lyon), Étienne Zurbach, Emmanuelle Hoareau (Marseille), Fabienne Bailly, Aurélien de Marne (Metz), Grégory Pfau (Paris), Guillaume Pavic (Rennes) and Guillaume Sudérie (Toulouse), participants in the French EWS and French-speaking online forums, including Psychoactif.org. Special thanks to Julie-Emilie Adès for her assistance and support in writing this text, together with her proofreading work. Reviewers: Julie-Emilie Adès, François Beck, Sylvain Gautier Documentation: Isabelle Michot Graphic designer: Frédérique Million Photo copyrights: © Bachellier Christian (CC), © zimnevan - Fotolia.com, © Frédérique Million (OFDT) Several pieces of information in this summary were taken from the I-TREND international research project, co-funded by the European Union. 2 INTRODUCTION This document summarises the available data on the 25x-NBOMe molecule group. 25x-NBOMe, or NBOMe, constitute a group of compounds (25I-NBOMe, 25B-NBOMe, etc.) belonging to the phenethylamines family1, which mainly has psychedelic effects2. These molecules are new psychoactive substances (NPS). Their diffusion has strongly increased over the past decade (Lahaie et al., 2013). These substances can have a much longer action duration than LSD, and are often sold and used as a substitute for the latter. 25I-NBOMe appears to be the most widely used compound in this group. This summary was drawn up based on the OFDT survey and monitoring schemes (TREND and SINTES network, I-TREND project3), available data collected from the EMCDDA (European Monitoring Centre for Drugs and Drug Addiction) and the national institutions working in the field of drugs, whether in the health sector (ANSM addiction monitoring, CAP-TV network, Santé Publique France, SFTA4) or in the law enforcement sector (SCL and INPS5).
[Show full text]
All Designer Drugs, Old and New
ALL DESIGNER DRUGS, OLD AND NEW written by Marcus Weiblen editing help/additional info by roionsteroids of reddit.com/r/Drugs Updates continue as of may 7th, 2014. if anyone has any other citable / reliable sources about any of these compounds or any other new drugs please let me know at marcus [dot] weiblen (at) gmail {dot} com and i'll try to keep this document updated throughout my hectic life. the document will to continue update here (if possible): https://www.dropbox.com/s/rzx3wpxfwuv2kww/designerdrugs.pdf (return to contents) CONTENTS: Foreword A Short Glossary / How to Read This Paper I: Stimulants / Empathogens (Dopamine/Noradrenaline Reuptake Inhibitors, 5-HT Releasers/Receptor Agonists) A. Substituted Cathinones B. Pyrrolidines/Pyrrolidinophenones C. Benzofurans D. Phenylpropylamines/piperidines E. Substituted Amphetamines F. Indanes/indoles G. Tropanes/*caines H. Piperazines I. Miscellaneous stimulants II: Psychedelic Hallucinogens (Serotonin 5-HT Receptor 2x Agonists) A. Phenethylamines 1. 2C-x series 2. Psychedelic Amphetamines 3. N-benzylated phenethylamines 4. Mescaline analogues 5. Conformationally-restricted derivatives B. Tryptamines 1. N-alkylated 2. 4-position substitutions 3. 5-position substitutions 4. LSD derivatives 5. alpha-position substitutions 6. 2-position substitutions 2 (return to contents) III: Sedatives (GABA Agonists / Modulators) IV: Analgesics (µ-Opioid Receptor Agonists) V: Synthetic Cannabinoids (CB /CB Agonists) 1 2 A. JWH series B. AM series C. Miscellaneous cannabinoids D. THJ series E. Endocannabinoid
[Show full text]